New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 11, 2012
05:31 EDTELN, BIIBBiogen, Elan TYSABRI data at ECTRIMS reaffirms positive effects for MS
Biogen Idec (BIIB) and Elan (ELN) announced that results from 11 company-sponsored TYSABRI presentations, including 10 posters and one platform, will be available for viewing at the 28TH Congress of the European Committee for Treatment and Research in Multiple Sclerosis, or ECTRIMS, in Lyon, France, Oct. 10-13. The data will further establish the benefits of TYSABRI in reducing relapse rates and slowing disease progression.
News For BIIB;ELN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
09:48 EDTBIIBBiogen should be bought on weakness after Roche drug halted, says Evercore ISI
Subscribe for More Information
08:53 EDTBIIBBiogen drug, trial differs from Roche Alzheimer's drug, says RBC Capital
Subscribe for More Information
08:51 EDTBIIBBiogen drops 2% after Roche discontinues Alzheimer drug trial
Shares of Biogen (BIIB) are moving lower after Roche (RHHBY) announced the discontinuation of its Alzheimer's drug gantenerumab, which was in Phase III testing. Analysts at Wells Fargo said Roche's trial failure adds risk to Biogen's potential treatment of Alzheimer's. Shares of Biogen are down $8.20 to $345.50 in pre-market trading.
December 12, 2014
08:01 EDTBIIBPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 9, 2014
12:22 EDTBIIBPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use